In small cell lung cancer (SCLC), the protein DLL3 is a promising target in the development of emerging therapies. In ...

Mitazalimab, in combination with standard chemotherapy, has exhibited continued promising efficacy and safety in treating ...

Survival and Progression Metrics: Secondary and exploratory endpoints include duration of response, sustained MRD negativity, biochemical and clinical progression-free survival (PFS), time to a ...

Michael Cole shares his decade-long battle with malignant pleural mesothelioma, highlighting treatment choices, resilience, and the vital doctor-patient relationship.

The study evaluated lifileucel in patients 18 years and older with unresectable or metastatic melanoma (stage IIIc or IV) who ...

Combination therapy with relatlimab and nivolumab enhances treatment-free survival in advanced melanoma, offering promising ...

The MEDALIST trial was a phase 3 study with patients with ESA-refractory, low-risk MDS who require transfusions. In this ...

The US FDA has approved imlunestrant (Inluriyo) for the treatment of adult patients with estrogen receptor (ER)-positive, ...

Iberdomide is a member of a new drug class in myeloma known as CELMoD agents, which build on the established platform of ...

FDA lifts REMS program for vandetanib, affirming safety in thyroid cancer treatment as healthcare providers ensure effective ...

The JAVELIN Bladder 100 trial established avelumab (Bavencio) as a standard switch maintenance therapy, according to Grivas.

Daratumumab-based regimens show significant clinical benefits for newly diagnosed, transplant-ineligible multiple myeloma ...